Mandarin Orange
Beta-cryptoxanthin-rich citrus tied to bone and metabolic health
Nutrition per serving 1 medium (88 g)
- Water 75 g86%
- Sugars 9.3 g11%
- Fibre 1.6 g2%
- Other carbs 0.8 g1%
- Protein 0.7 g1%
- Fat 0.3 g0%
| Nutrient | Per serving | % daily value |
|---|---|---|
| Vitamin C | 24 mg | 26% |
| Beta-cryptoxanthin | 358 mcg | 0% |
| Potassium | 146 mg | 3% |
| Fiber | 1.6 g | 6% |
| Folate | 14 mcg DFE | 4% |
| Vitamin A | 30 mcg RAE | 3% |
| Calcium | 33 mg | 3% |
| Total sugars | 9.3 g | 0% |
| Thiamin | 0.05 mg | 4% |
Composition data: USDA FoodData Central ↗
What is Mandarin Orange?
Mandarin Orange (Citrus reticulata) is a fruit used for higher beta-cryptoxanthin intake (a marker of mandarin consumption) is associated with lower osteoporosis and hip-fracture risk in pooled observational studies. NutriDex grades the human evidence as Moderate. Mandarins are a leading dietary source of beta-cryptoxanthin, and pooled observational data link higher beta-cryptoxanthin intake to lower osteoporosis risk (OR ~0.79) and fewer hip fractures, while the Japanese Mikkabi cohort associates higher serum beta-cryptoxanthin with reduced insulin resistance, liver dysfunction, metabolic syndrome and type 2 diabetes. Citrus flavanones such as hesperidin are inversely associated with stroke in prospective cohorts (about 11% lower risk per 50 mg/day), and hesperidin trials show modest improvements in lipids, glucose and inflammatory markers. The whole fruit reliably supplies vitamin C, folate, potassium and soluble pectin fibre. However, almost all disease-outcome evidence is observational and cannot establish causation; the strongest mandarin-specific data come from a single Japanese region (Mikkabi) and may not generalize. Intervention trials typically use isolated hesperidin or fortified juice rather than whole mandarins, are short-term, and report modest effects confounded by overall healthy diet patterns. Vitamin C does not prevent colds in the general population, only modestly shortening duration. Overall the human evidence is moderate—consistent cohorts plus supportive but limited RCTs—rather than definitive.